Aim: Atherosclerosis (AS) characterized as a chronic inflammatory disease. Multiple immune cells and inflammatory cytokines, such as high mobility group protein (HMGB1), regulatory T (Treg) cells, T helper (Th17) cells, and inflammation-related cytokines, play a key role in its pathophysiology. A large number of studies report that HMGB1 and Th17 cells may promote atherosclerosis progression, whereas Treg cells may play a protective role in atherosclerosis; thus, alterations in the Treg/Th17 ratio may exist in atherosclerosis diseases. Up till now, the relationships between HMGB1 levels and the Treg/Th17 ratio remain incompletely understood. The major purpose of this study was to investigate the relationship between HMGB1 levels and the Treg/Th17 ratio in patients with coronary artery atherosclerotic plaques.

Methods: We enrolled patients with coronary atherosclerosis and normal coronary artery as the research subjects. Flow cytometry was used to analyze the Treg cells, the Th17 cells frequency, and the Treg/Th17 ratio. Otherwise, real-time polymerase chain reaction was used for assays the mRNA expressions of HMGB1, retinoic acid-related orphan nuclear receptor C (RORC), and forkhead-winged helix transcription factor (Foxp3). Moreover, enzyme-linked immunosorbent assays were used to detect the level of protein and cytokines, such as HMGB1, IL-10, TGF-β1, IL-17A, and IL-23.

Results: Using flow cytometry, we observed a significantly increased of Th17 cell frequency, whereas Treg cell frequency significantly decreased in atherosclerotic patients. Consistently, the levels of RORC mRNA were significantly increased in coronary atherosclerosis (AS) group compared to normal coronary artery (NCA) group (P<0.01). In contrast, the expression of Foxp3 mRNA was markedly lower in the AS group than in the NCA group (P<0.01). Furthermore, we observed the serum concentrations of HMGB1, IL-17A, and IL-23 were significantly higher in the AS group than in the NCA group (P<0.01, respectively), whereas the concentrations of serum IL-10 and TGF-β1 were significantly lower in the AS group than in the NCA group (P<0.01, respectively). In addition, we also found that HMGB1 levels showed negative correlation with the Treg/Th17 ratio in the two groups (r = -0.6984, P<0.01).

Conclusions: The data in our study indicated that HMGB1 may promote atherosclerosis progression via modulating the imbalance in the Treg/Th17 ratio.


Key words: AS, HMGB1, Treg cells, Th17 cells
High mobility group box-1 protein (HMGB1), an evolutionarily conserved non-histone DNA-binding protein that functions as a DNA chaperone, is found in most cells and plays a vital role in numerous key DNA events, such as nucleosome stability and sliding, DNA replication and repair, gene transcription and so on. HMGB1, derived from necrotic and damage cells (passively released) and activated macrophages/microphages (actively secrete), is involved in the pathological progression of tumor metastasis and invasion, hepatitis B virus infection, atherosclerosis, restenosis of injured vasculature, and angiogenesis after myocardial infarction.

Treg cells and Th17 cells belong to CD4⁺ T cells subset, which can mediate immune responses, contribute to the development of atherosclerotic plaques. Forkhead family protein 3 (Foxp3) and retinoic acid-related orphan receptor γt (RORγt) are the transcriptional factors of Treg cells and Th17 cells, respectively. Treg cells play a pivotal role in maintaining the immune tolerance and immune homeostasis, whereas Th17 cells repress the function of Treg cells and contribute to the inflammatory diseases.

Studies by other research groups as well as our own previous studies demonstrate that HMGB1 levels are increased in acute myocardial infarction and coronary artery stenosis. However, how HMGB1 affects atherosclerosis progression remains unclear. Recently, several studies show that Th17 cells and Treg cells can transform into each other during inflammatory environment and autoimmune diseases. Thus, we hypothesize that HMGB1 may regulate the atherosclerosis plaque formation via modulating Treg cells conversion to Th17 cells in vivo. The major purpose of this study is to investigate the relationship between HMGB1 levels and the Treg/Th17 ratio in atherosclerotic plaques.

Materials and Methods

Patient Population

Commonly, sites with low or oscillatory endothelial shear stress, located near branch points and along inner curvatures, are most susceptible, and the abdominal aorta, coronary arteries, iliofemoral arteries, and carotid bifurcations are typically affected the most. In our study, we enrolled 66 patients (34 males and 32 females) derived from central people’s hospital in Yichang, Hubei Province, China. All of them gave written consent informs to this study and all the experiments were approved by the research Ethics Committee of the central people’s hospital in Yichang, Hubei Province, China. Thus, we enrolled the patients with coronary artery diseases diagnosed by coronary angiography as the research subjects. Their ages ranged from 39 to 71 years (mean age = 59.5 ± 8.7 years). Patients were classified into two groups: group 1: coronary atherosclerosis (AS), patients were diagnosed by coronary angiography and displayed one or more coronary arteries with at least 50% stenosis; group 2: normal coronary arteries (NCA), patients were diagnosed by coronary angiography and no vascular diseases were observed in them.

The exclusion criteria were as follows: diabetes mellitus and other metabolic diseases; cardiovascular events <1 year, such as a stroke or myocardial infarction; malignant diseases; renal failure; liver diseases; various chronic and acute infections; connective tissue diseases; surgery; treatment with anti-inflammatory drugs and/or immunosuppressive agents.

Blood Samples

We collected 5–10 mL of peripheral blood from the all participants after an overnight fast. Blood samples were treated with sodium heparin and examined within 4 h. The anti-coagulated blood is for flow cytometry and real-time polymerase chain reaction (qRT-PCR). Otherwise, serum obtained from 2 mL without anticoagulant for enzyme-linked immunosorbent assay (ELISA) stored at −80°C until use.

Isolation of Peripheral Blood Mononuclear Cells (PBMCs)

PBMCs were isolated from 5 mL of sodium heparin-treated venous blood samples by Ficoll–Hypaque gradient centrifugation (1,800 rpm at room temperature for 20 min). Washed and resuspended at a density of 2 × 10⁶ cells/mL in 1640 complete culture medium (RPMI 1640 supplemented with 100 U/mL streptomycin, 100 U/mL penicillin, 2 mM glutamine, and 10% heat-inactivated fetal calf serum) (Lot 31800-022, Gibco, America).

Cell Culture

For Th17 analysis, PBMCs were suspended at a density of 2 × 10⁶ cells/mL in complete culture medium. The cell suspension was transferred to 12-well plates. Then, cell suspension were stimulated with PMA/Ionomycin mixture (Lot LK-CS1001, Liankebio, China) 4 µL/mL for 6 h in the presence of BFA/Monensin mixture (4 µL/mL, Lot LK-CS1002, Liankebio, China) in an incubator with 5% CO₂ at 37°C. Then the contents were collected and transferred to 15-mL sterile tubes and washed twice in phosphate-buffered saline (PBS) and prepared for Th17 cells analysis.
Flow Cytometry
FITC-conjugated anti-human CD3 (Lot 11-0039-42), APC-conjugated anti-human CD8 (Lot 17-0088-42), PE-conjugated anti-human IL-17A (Lot 85-12-7178-42), FITC-conjugated anti-human CD4 (Lot 85-11-0047-42), PE-conjugated anti-human CD25 (Lot 85-12-0259-42) and PE-CY7-conjugated anti-human CD127 (Lot 85-25-1278-42) are all purchased from eBioscience, America. For the analysis of Th17, the cells were incubated with anti-human CD3-FITC and anti-human CD8-APC at 4°C for 30 min. After the surface staining, cells were fixed and permeabilized with Fix/Perm buffer (Lot: 88-8824, eBioscience, America) according to the manufacturer’s instruction. The cells were incubated with anti-human IL-17A-PE for intracellular staining. For T reg analysis, the cells were incubated with anti-human CD3-FITC, anti-human CD4-FITC, anti-human CD8-APC at 4°C for 30 min. The cells were incubated with anti-human CD3-FITC and anti-human CD8-APC at 4°C for 30 min. The cells were incubated with anti-human CD3-FITC, anti-human CD25-PE, and anti-human CD8-APC at 4°C for 30 min. After the surface staining, cells were fixed and permeabilized with Fix/Perm buffer (Lot: 88-8824, eBioscience, America) according to the manufacturer’s instruction and stained with anti-human IL-17A-PE for intracellular staining. For T reg analysis, the cells were incubated with anti-human CD3-FITC, anti-human CD4-FITC, anti-human CD8-APC at 4°C for 30 min. The cells were incubated with anti-human CD3-FITC, anti-human CD25-PE, and anti-human CD8-APC at 4°C for 30 min. After the surface staining, cells were fixed and permeabilized with Fix/Perm buffer (Lot: 88-8824, eBioscience, America) according to the manufacturer’s instruction.

qRT-PCR
The mRNA levels of HMGB1, FOXP3, and RORC were determined by qRT-PCR analysis. Total RNA was extracted from PBMCs with Trizol reagent (Takara) and converted into cDNA using a PrimeScript RT reagent kit (Lot 00171359, Sigma, America) according to the manufacturer’s instructions. The mRNA expressions of HMGB1, Foxp3, and RORC were quantified using the SYBRPre mix ExTaq (Lot AK8306, Takara, Japan) on an Agilent SureCycler 8800 system (Agilent, American), with GAPDH expression as a control. Amplification was performed in a total volume of 25 µL for 40 cycles of 15 s at 95°C, 30 s at 59°C, and 30 s at 60°C after initial denaturation (95°C, 30 s). The primer sequences were as follows: GAPDH (purchased from Sangon Biotech, China, Lot PHS04); HMGB1 forward: AACCTATATCCCTCCAAAAG; HMGB1 reverse: ACATCTCTCCAGTTTCTTC (NM_002128.4); Foxp3 forward: AACAGCA-CATTCCACAGTTTCTTC; Foxp3 reverse: CATTGAGTTCCGCTGCTTC (NM_014009.3); RORC forward: CCGAGATGAGATTGCCCTCT; RORC reverse: GGTGGCAGCTTTGCCAGGAT (NM_002128.4). Samples were analyzed in triplicate; 2^{ΔΔCT} was used to calculate fold change of mRNA expression.

Measurement of Blood Biochemistry
The level of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), and fasting plasma glucose (FPG) were measured by enzymatic methods. All of them were measured at a clinical laboratory.

Cytokines in Serum Determined by ELISA
Serum levels of TGF-β1, IL-10, IL-17A, IL-23, and HMGB1 were measured by commercially available ELISA kits according to the manufacturer’s instruction. All samples were assessed in triplicate. The human TGF-β1 (Lot EHC107b.96), IL-10 (Lot EHC009.96), IL-17A (Lot EHC170.96), and IL-23 (Lot EHC171.96) ELISA kits were purchased from NeoBioscience China, whereas the HMGB1 ELISA kit was purchased from Westang, China (Lot F01020). The data were recorded at 450 nm in a microplate reader (Thermo, Finland). The sensitivity levels for TGF-β1 (Lot AK8306, Takara, Japan) on an Agilent SureCycler 8800 system (Agilent, American), with GAPDH expression as a control. Amplification was performed in a total volume of 25 µL for 40 cycles of 15 s at 95°C, 30 s at 59°C, and 30 s at 60°C after initial denaturation (95°C, 30 s). The primer sequences were as follows: GAPDH (purchased from Sangon Biotech, China, Lot PHS04); HMGB1 forward: AACCTATATCCCTCCAAAAG; HMGB1 reverse: ACATCTCTCCAGTTTCTTC (NM_002128.4); Foxp3 forward: AACAGCA-CATTCCACAGTTTCTTC; Foxp3 reverse: CATTGAGTTCCGCTGCTTC (NM_014009.3); RORC forward: CCGAGATGAGATTGCCCTCT; RORC reverse: GGTGGCAGCTTTGCCAGGAT (NM_002128.4). Samples were analyzed in triplicate; 2^{ΔΔCT} was used to calculate fold change of mRNA expression.

Table 1. Clinical characteristics of the groups

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>NCA (n=33)</th>
<th>AS (n=33)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (Male/Female)</td>
<td>16/17</td>
<td>19/14</td>
</tr>
<tr>
<td>Age, mean ± SD years</td>
<td>61.4±9.5</td>
<td>58.6±7.8</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>11 (33.3%)</td>
<td>19 (57.6%)</td>
</tr>
<tr>
<td>FPG (mmol/L)</td>
<td>5.3±0.5</td>
<td>5.2±0.5</td>
</tr>
<tr>
<td>Serum Cr (umol/L)</td>
<td>71.7±15.4</td>
<td>75.0±13.3</td>
</tr>
<tr>
<td>TC (mmol/L)</td>
<td>4.0±1.0</td>
<td>4.0±0.9</td>
</tr>
<tr>
<td>TG (mmol/L)</td>
<td>1.4±0.8</td>
<td>1.2±0.4</td>
</tr>
<tr>
<td>HDL-C (mmol/L)</td>
<td>1.4±0.3</td>
<td>1.5±0.2</td>
</tr>
<tr>
<td>LDL-C (mmol/L)</td>
<td>2.0±0.6</td>
<td>2.0±0.7</td>
</tr>
</tbody>
</table>

Values are expressed as mean ± SD. NCA: normal coronary arteries; AS: coronary atherosclerosis; FPG: fasting plasma glucose; Cr: creatinine; TC: total cholesterol; TG: triglycerides; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol.

Statistical Analysis
All data analyses were performed by SPSS statistical software (version 13). Data for continuous variables are presented as the mean ± standard deviation (SD). Group comparison was conducted with Student’s t test. The correlation between serum HMGB1 and the Treg/Th17 ratio was described by Pearson correlation coefficients. A two-tailed p-value of <0.05 was considered to be the significance level.

Results
The Characteristics of Participants
There were no significant differences in age, gender, risk factors, and blood biochemical parameters between patients in the NCA and AS groups (Table 1).
Increased Th17 Frequency and Decreased Treg Frequency in PBMC of Coronary Atherosclerosis Patients

As shown in Fig. 1, the frequencies of Th17 (CD3⁺CD8⁻IL17⁺/CD3⁺CD8⁻T cells) was significantly higher in AS group (1.6% ± 0.4%) than in the normal coronary arteries (NCA) group (0.9% ± 0.2%) (P<0.01). The frequency of Treg cells (CD4⁺CD25⁺CD127⁻/CD4⁺T cells) was markedly decreased in the AS group (4.3% ± 0.7%) compared to the NCA group (6.2% ± 0.8%) (P<0.01). As shown in Fig. 1, we found that the Treg to Th17 ratio cells was lower in the AS group (2.8 ± 1.0) than in the NCA group (7.1 ± 1.9). Therefore, the Treg/Th17 ratio was signifi-
cantly decreased in patients in the AS group as than in those in the NAC group ($P<0.01$).

**The Expression of HMGB1, RORC, and Foxp3 mRNA in PBMC**

HMGB1 is the important inflammatory cytokine in atherosclerotic diseases. RORC and Foxp3 are the specific transcription factors of Th17 and Treg cells, respectively. We thus measured the expressions of HMGB1, RORC, and Foxp3 mRNA in PBMCs from the all participants. As shown in Fig. 2, the levels of HMGB1 and RORC mRNA were significantly increased in the AS group than in the NCA group (both $P<0.01$). In contrast, the expression of Foxp3 mRNA was markedly lower in the AS group than in the NCA group ($P<0.01$).

**The Level of Cytokines in the Serum from Patients**

Serum levels of TGF-$eta$1, IL-10, IL-17A, IL-23, and HMGB1 were detected in the all participants by means of ELISA tests (Fig. 3). The HMGB1, IL-17A, and IL-23 concentrations in the AS group (HMGB1: 5.45±1.36 ng/mL; IL-17A: 50.78±8.52 pg/mL; IL-23: 25.52±3.93 pg/mL) were significantly higher than those in the NCA group (HMGB1: 2.33±0.66 ng/mL; IL-17A: 16.45±3.00 pg/mL; IL-23: 14.85±1.74 pg/mL; $P<0.01$), whereas serum IL-10 and TGF-$eta$1 concentrations in the AS group (IL-10: 1.12±0.06 pg/mL; TGF-$eta$1: 3013.78±567.54 pg/mL) were significantly lower than those in the NCA group (IL-10: 1.48±0.17 pg/mL; TGF-$eta$1: 6678.04±1178.09 pg/mL; $P<0.01$).

**Correlations between HMGB1 and the Treg/Th17 Ratio and Their Related Cytokines**

As shown in Fig. 4, HMGB1 concentration showed negative correlation with Treg cells in the two groups ($r=-0.6362$, $P<0.01$, Fig. 4A) and positive correlation with the frequencies of Th17 cells ($r=0.6057$, $P<0.01$, Fig. 4B). Consistently, HMGB1 concentrations showed negative correlation with the Treg/Th17 ratio in the two groups ($r=-0.6984$, $P<0.01$, Fig. 4C).

**Discussion**

The present data demonstrate that AS patients exhibited significantly increasing serum level of HMGB1, peripheral Th17 frequency, Th17-related cytokines (IL-17 and IL-10), and transcription factor (RORC) levels; in addition, AS patients also showed dramatically decreases in the Treg frequency, Treg-related cytokine (TGF-$eta$1 and IL-10) and transcription factor (Foxp3) levels than the NCA group. Otherwise, the data also provides that the balance between circulating Treg/Th17 cells is impaired in these patients. More importantly, the level of serum HMGB1 negatively correlated with the Treg/Th17 ratio. These
inflammatory mediator. In addition, it functions as a pro-inflammatory molecule in several diseases, such as diabetic cardiomyopathy, various liver diseases, active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), and cardiovascular diseases and so on. Atherosclerosis, a disease of the large/medium arteries, is a chronic inflammatory disease involved in endothelial cells (ECs), vascular smooth muscle cells (VSMCs), monocytes/macrophage, platelets, and other molecules. HMGB1 mediates chronic inflammatory mediator. In addition, it functions as a pro-inflammatory molecule in several diseases, such as diabetic cardiomyopathy, various liver diseases, active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), and cardiovascular diseases and so on. Atherosclerosis, a disease of the large/medium arteries, is a chronic inflammatory disease involved in endothelial cells (ECs), vascular smooth muscle cells (VSMCs), monocytes/macrophage, platelets, and other molecules. HMGB1 mediates chronic inflammatory mediator.

results suggest that HMGB1 may promote the process of atherosclerosis by disturbing the Treg/Th17 ratio, which may be the new pathogenesis of atherosclerosis and new target of atherosclerosis treatment.

HMGB1 is found in most cells and plays a vital role in numerous key DNA events, such as nucleosome stability and sliding, DNA replication and repair, and gene transcription. In addition to the nuclear role, cytoplasmic HMGB1 released by activated immune and non-immune cells, functions as a later inflammatory mediator. In addition, it functions as a pro-inflammatory molecule in several diseases, such as diabetic cardiomyopathy, various liver diseases, active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), and cardiovascular diseases and so on. Atherosclerosis, a disease of the large/medium arteries, is a chronic inflammatory disease involved in endothelial cells (ECs), vascular smooth muscle cells (VSMCs), monocytes/macrophage, platelets, and other molecules. HMGB1 mediates chronic inflammatory mediator.

Fig. 3. The levels of serum HMGB1, IL-17A, IL-23, IL-10, and TGF-β1 in coronary atherosclerosis (AS) patients. (A) Serum HMGB1 level significantly increased in the AS group compared to the normal coronary arteries (NCA) group (P<0.01); (B) Serum IL-17A level significantly increased in the AS group compared to the NCA group (P<0.01); (C) Serum IL-23 level significantly increased in the AS group than in the NCA group (P<0.01); (D) Serum IL-10 level significantly decreased in the AS group compared to the NCA group (P<0.01); (E) Serum TGF-β1 level significantly decreased in the AS group compared to the NCA group (P<0.01); *: P<0.01 is considered statistically significant.
inflammatory responses in the above mentioned cells, and it plays a vital role in atherosclerosis progression\textsuperscript{19-21}. In this study, our data confirmed that the level of HMGB1 mRNA and the expression of HMGB1 increased in AS patients, in comparison with the NCA patients. Our results are consistent with the conclusion of other investigators\textsuperscript{22, 23}. Hence, HMGB1 may promote atherosclerosis progression although the mechanisms remain unclear.

In human beings, interleukin 6 (IL-6) and transforming growth factor-\( \beta \) (TGF-\( \beta \)) have been shown to promote the differentiation of Th17 cells, IL-23 is reported to maintain the development of Th17, whereas CD4\(^+\) T cells have been shown to be transformed to Treg cells in the presence of TGF-\( \beta \)\textsuperscript{24}. Th17 cells function as pro-inflammatory cells via the production of IL-17, tumor necrosis factor (TNF\( \alpha \)), and IL-6\textsuperscript{25}. On the other hand, Treg cells play the anti-inflammatory role by achieving direct contact with cells or via releasing anti-inflammatory cytokines, such as IL-10 and TGF-\( \beta \)\textsuperscript{25}. Several studies have demonstrated that Treg cells and Th17 cells are involved in atherosclerosis progression\textsuperscript{26, 27}. In our study, we found that the level of Treg cells frequency decreased significantly in AS patients compared to NCA patients, whereas the frequency of Th17 cells increased in AS patients compared to NCA patients. On the other hand, the Treg/Th17 ratio decreased in the AS patients than in the NCA patients. Moreover, RORC and Foxp3 are the transcription factors of Th17 cells and Treg cells respectively. In our study, the level of RORC mRNA was upregulated but the level of Foxp3 mRNA was downregulated in the AS patients. Consistently, Th17-cell–related cytokine, such as IL-17, increased in AS patients, whereas Treg-cell–related cytokines, such as IL-10 and TGF-\( \beta \), decreased in AS patients. The results we observed in this study were consistent with those of many other studies\textsuperscript{13, 27, 28}. It was suggested that Treg cells and Th17 cells play a vital role in the development of atherosclerosis, and the balance between Treg cells and Th17 cells was disturbed in patients AS patients. The underlying mechanism needs to be further investigated in the future.

Recently, a great deal of evidence shows that HMGB1, via regulating the balance between Treg and Th17 cells, may modulate the progression of several diseases, such as experimental autoimmune myocarditis, rheumatoid arthritis, and chronic hepatitis B\textsuperscript{29-31}. It is suggested that HMGB1 may promote the disequilibrium between Treg and Th17 cells in these diseases. Consistently, we found that serum HMGB1 levels were positively correlated to Th17 frequency and RORC mRNA levels, whereas they were correlated to Treg frequency and Foxp3 mRNA levels in AS patients. Moreover, serum HMGB1 levels were also negatively correlated to the Treg/Th17 ratio. On the basis of our results, we can conclude that HMGB1
may promote atherosclerosis progression by modulating the imbalance between Treg and Th17 cells. Recently, we find that several researchers have clarified the related underlying mechanisms among other diseases. Li et al. has found that in patients with chronic hepatitis B, HMGB1 may promote Th17 differentiation via the TLR4-IL-6 pathway. Meanwhile, chronic hepatitis B, HMGB1 may promote Th17 differentiation of Th17 by enhancing the TLR2 pathway in patients with rheumatoid arthritis. In addition, Zhu et al. has found that HMGB1 modulates the suppressive capacity of CD4^+CD25^+Tregs via the TLR4 pathway. However, the mechanism as to how HMGB1 affects the differentiation of Th17 in atherosclerosis diseases remains unclear; this needs to be more investigated in the future.

Although we observed relationships between serum HMGB1 levels and the Treg/Th17 ratio balance in atherosclerotic diseases, the underlying mechanism as to how HMGB1 modulates the differentiation and quantity of Treg cells and Th17 cells needs to be further investigated. We'll focus on the study of mechanism to find new targets for the diagnosis and treatment of atherosclerotic diseases.

**Acknowledgments**

This work was supported by the Natural Science Foundation of Hubei Province, China (2014CFC1035), and the National Natural Science Foundation of China (81400794).

**Conflict of Interest**

The authors have no financial conflicts of interest.

**References**

18) Lusis AJ: Atherosclerosis. NATURE, 2000; 407: 233-241
19) Luo Y, Li SJ, Yang J, Qiu YZ, Chen FP: HMGB1 induces

20) Yang J, Chen L, Ding J, Rong H, Dong W, Li X: High mobility group box-1 induces migration of vascular smooth muscle cells via TLR4-dependent PI3K/Akt pathway activation. Mol Biol Rep, 2012; 39: 3361-3367


24) Dong C: Differentiation and function of pro-inflammatory Th17 cells. Microbes Infect, 2009; 11: 584-588


31) Li J, Wang FP, She WM, Yang CQ, Li L, Tu CT, Wang JY, Jiang W: Enhanced high-mobility group box 1 (HMGB1) modulates regulatory T cells (Treg)/T helper 17 (Th17) balance via toll-like receptor (TLR)-4-interleukin (IL)-6 pathway in patients with chronic hepatitis B. J Viral Hepat, 2014; 21: 129-140